Cullinan Therapeutics Inc. (CGEM) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Cullinan Therapeutics Inc. (NASDAQ: CGEM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $15.03 (-2.72% 1D, market cap $994.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CGEM ranks #772 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEM carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ODTX (Odyssey Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $953.0M) and PRME (Prime Medicine Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, CGEM leads on earnings multiple (N/A) while CGEM leads on capital efficiency (-35.0% ROIC).
Per CGEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789972), Cullinan Therapeutics Inc. generated $0 in revenue, -$219.9M in net income, and -$175.8M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CGEM currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($17.78) and Max Pain ($15.78) forces dealer call-delta covering toward $24.35.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cullinan Therapeutics Inc. (CGEM) dropped -2.72% to $15.03, trading at 50% of its 52-week range ($6.73 – $23.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Cullinan Therapeutics reported that the U.S. FDA and Australian TGA cleared a global Phase 1b/2a trial of velinotamig in adults with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia,
Cullinan Therapeutics (CGEM) is back in focus after regulators in the U.S. and Australia cleared a global Phase 1b/2a trial of velinotamig in difficult immune thrombocytopenia and warm autoimmune hemolytic anemia. Cullin
Cullinan Therapeutics has more than doubled over the past year, which puts a sharp spotlight on whether that move still lines up with the strength of its balance sheet and book value. After a series of clinical updates,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CGEM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CGEM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Cullinan Therapeutics Inc. (CGEM) ranks #772 by composite RQD confidence (32/100, grade E) and #362 by equity capitalization ($994.3M). Within this direct 5-issuer industry benchmark cohort, CGEM leads on earnings valuation at N/A trailing P/E, while CGEM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CGEM at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CGEM
ACTIVE
Cullinan Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -2.72% | $994.3M | Benchmark Subject |
| ODTX Odyssey Therapeutics Inc. | D+ | 52/100 | — | — | — | -1.46% | $953.0M | /odtx-vs-cgem → |
| PRME Prime Medicine Inc. | E | 31/100 | — | — | -35.0% | -9.92% | $950.4M | /prme-vs-cgem → |
| MGTX MeiraGTx Holdings plc | E | 21/100 | — | — | -35.0% | -2.21% | $932.1M | /mgtx-vs-cgem → |
| GLUE Monte Rosa Therapeutics Inc. | E | 27/100 | — | — | -35.0% | -1.01% | $927.4M | /glue-vs-cgem → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cullinan Therapeutics Inc. (CGEM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$219.9M, operating cash flow of -$175.8M, and free cash flow of -$175.8M (-21.0% YoY). On the balance sheet, CGEM closed FY2025 with $448.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$219.9M | -$175.8M | -$175.8M | $448.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$167.6M | -$145.3M | -$145.3M | $621.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$155.1M | -$134.3M | -$134.3M | — | — |
As of 2026-11-02, Cullinan Therapeutics Inc. (NASDAQ: CGEM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $15.03 (-2.72% 1D, market cap $994.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CGEM ranks #772 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEM carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ODTX (Odyssey Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $953.0M) and PRME (Prime Medicine Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, CGEM leads on earnings multiple (N/A) while CGEM leads on capital efficiency (-35.0% ROIC).
Per CGEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789972), Cullinan Therapeutics Inc. generated $0 in revenue, -$219.9M in net income, and -$175.8M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CGEM last traded at $15.03 (-2.72% on volume of 389,442 shares), positioning the stock -15.47% below its 50-day simple moving average ($17.78) and -5.05% below its 200-day simple moving average ($15.83). Across its 52-week range of $6.73 to $23.19, CGEM sits at the 50.4% percentile with a 14-day RSI of 48.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.15 to $16.91).
Why CGEM Stock dropped -2.72% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, CGEM scores 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows:
Investment implication: the rating frames CGEM as a forensic-risk name. Upside would require a reversal in cash burn and insider/institutional conviction, none of which the source data shows as having begun. Valuation tradeoffs center on a $994.3M market capitalization against negative operating and free cash flow; the absence of earnings-based multiples means conventional valuation anchors cannot be applied from the source data alone.
Cullinan Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the profile. The source data does not identify its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M across the available periods, so the source data does not show commercial sales.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-241.6M | $-219.9M | N/A | $-175.8M | $88.3M | N/A |
| FY 2024 | $0.0M | $-196.9M | $-167.6M | N/A | $-145.3M | $83.0M | N/A |
| FY 2023 | $0.0M | $-191.1M | $-155.1M | N/A | $-134.3M | N/A | N/A |
Per the SEC financials, the company reported operating and net losses in every period shown, with losses widening from FY 2023 to FY 2025. Gross, operating, and net margins are each 0% per the market data. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2 of 9. Per the SEC financials, reported cash was $88.3M at FY 2025, and the source data does not provide debt figures for any period.
Per the recent news and catalysts data, five items reference CGEM, each tagged YELLOW with a MARKET WIRE impact label, from sources including Yahoo! Finance Canada, Yahoo Finance UK, TradingView, Simply Wall St, and MarketBeat. Headlines reference stock price and news coverage, a shares gap-up report, an FDA filing progress analysis, and a BTIG Buy rating with a $41 price target. The summaries are generic market-coverage descriptions and do not contain specific trial, filing, or financing details. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream or downstream dependencies, sector correlations, or second-order bottlenecks. The only sector context is the classification itself: Health Care, Biotechnology: Biological Products. A prospective investor should note that FDA-related coverage appears in the news wire, but the source data does not connect that coverage to any specific supply-chain node.
Per the analyst data section, no analyst data is available. The news wire references a BTIG Buy rating with a $41 price target, but the analyst data section itself is empty and does not provide a consensus rating. Per the holders section, no holder data is available, so SEC Form 4 insider trades, 13F institutional holdings, and Congressional trades are not available in source data.
Real-time company headlines, analyst actions, and sector developments for Cullinan Therapeutics Inc. (CGEM) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Cullinan Therapeutics reported that the U.S. FDA and Australian TGA cleared a global Phase 1b/2a trial of velinotamig in adults with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia,
Welcome to the CGEM (Cullinan Therapeutics Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CGEM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cullinan Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CGEM, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $15.45 (52-wk range $6.73 - $23.19), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).